Turning Point Therapeutics, Inc.
TPTXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for TPTX. That does not mean none is planned.
Get an email about TPTX's next catalysts
Track Turning Point Therapeutics (TPTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Oral repotrectinib (TPX-0005) | Phase 2 | Locally Advanced Solid Tumors | - | - |
Frequently asked questions
What is in Turning Point Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Turning Point Therapeutics, Inc.'s (TPTX) pipeline across Phase 2. Its lead program is Oral repotrectinib (TPX-0005) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Turning Point Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Turning Point Therapeutics, Inc. (TPTX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track TPTX biotech catalysts?→
Add TPTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Turning Point Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.